BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

...as EVP and general counsel. She was SVP of corporate affairs and general counsel at Aptevo Therapeutics Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:NVCN) 3/13/19 $5.0 $13.8 $14.7 7% Apellis Pharmaceuticals Inc. (NASDAQ:APLS) 3/7/19 $117.3 $1,074.2 $1,602.3 49% Aptevo Therapeutics Inc....
BioCentury | May 4, 2018
Targets & Mechanisms

Solid hopes for T cell bispecifics

...OTCQX:RHHBY), AMG 211 from Amgen, ERY974 from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) and APVO414 from Aptevo Therapeutics Inc....
...NYSE:NVS; SIX:NOVN) XmAb14045 Interleukin-3 receptor alpha (CD123) Hematologic malignancies Phase I Primary completion July 2019 Aptevo Therapeutics Inc....
BioCentury | Apr 26, 2018
Product R&D

Brake for gas

...mAb and a 4-1BB agonist. It is in Phase I testing for HER2-positive solid tumors. Aptevo Therapeutics Inc....
...Mentioned Alligator Bioscience AB (NASDAQ:OMX; SSE:ATORX), Lund, Sweden American Association for Cancer Research, Philadelphia, Pa. Aptevo Therapeutics Inc....
...TNFα - Tumor necrosis factor α Karen Tkach Tuzman, Associate Editor Alligator Bioscience AB American Association for Cancer Research Aptevo Therapeutics Inc. AstraZeneca...
BioCentury | Sep 8, 2017
Company News

Aptevo regains rights to MOR209/ES414 from MorphoSys

...with MorphoSys AG (Xetra:MOR; Pink:MPSYY) granting the German company worldwide rights to APVO414 (formerly MOR209/ES414). Aptevo...
...through Stage 1 of an ongoing Phase I trial to treat metastatic castration-resistant prostate cancer. Aptevo...
...8, 2016 ). Aptevo Therapeutics Inc. (NASDAQ:APVO), Seattle, Wash. MorphoSys AG (Xetra:MOR; Pink:MPSYY), Martinsried, Germany Business: Cancer Shannon Lehnbeuter MOR209/ES414 Aptevo Therapeutics Inc. Emergent...
BioCentury | Oct 24, 2016
Emerging Company Profile

RORing against resistance

...said. Breitmeyer declined to compare cirmtuzumab to other ROR1 inhibitors, including a bispecific protein from Aptevo Therapeutics Inc....
...of use for cirmtuzumab and TK216 Companies and Institutions Mentioned AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Aptevo Therapeutics Inc....
BioCentury | Aug 8, 2016
Company News

Emergent BioSolutions, Aptevo deal

...completed its spin out of newco Aptevo, which will house Emergent’s oncology and hematology assets. Aptevo’s...
...and CD3, which is in Phase I testing to treat metastatic castration-resistant prostate cancer. Aptevo...
...to develop ES414. Ixinity is a Factor IX replacement. Emergent shareholders received one share of Aptevo...
BioCentury | Aug 8, 2016
Financial News

Aptevo completes debt financing

...Hematology, Autoimmune Date completed: 2016-08-04 Type: Debt financing Raised: $20 million Investor: MidCap Financial Note: Aptevo...
BioCentury | Jan 22, 2016
Company News

Management tracks

...management team for planned oncology and hematology spinout Aptevo Therapeutics Inc. Emergent director Martin White will be Aptevo's...
Items per page:
1 - 9 of 9
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

...as EVP and general counsel. She was SVP of corporate affairs and general counsel at Aptevo Therapeutics Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:NVCN) 3/13/19 $5.0 $13.8 $14.7 7% Apellis Pharmaceuticals Inc. (NASDAQ:APLS) 3/7/19 $117.3 $1,074.2 $1,602.3 49% Aptevo Therapeutics Inc....
BioCentury | May 4, 2018
Targets & Mechanisms

Solid hopes for T cell bispecifics

...OTCQX:RHHBY), AMG 211 from Amgen, ERY974 from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) and APVO414 from Aptevo Therapeutics Inc....
...NYSE:NVS; SIX:NOVN) XmAb14045 Interleukin-3 receptor alpha (CD123) Hematologic malignancies Phase I Primary completion July 2019 Aptevo Therapeutics Inc....
BioCentury | Apr 26, 2018
Product R&D

Brake for gas

...mAb and a 4-1BB agonist. It is in Phase I testing for HER2-positive solid tumors. Aptevo Therapeutics Inc....
...Mentioned Alligator Bioscience AB (NASDAQ:OMX; SSE:ATORX), Lund, Sweden American Association for Cancer Research, Philadelphia, Pa. Aptevo Therapeutics Inc....
...TNFα - Tumor necrosis factor α Karen Tkach Tuzman, Associate Editor Alligator Bioscience AB American Association for Cancer Research Aptevo Therapeutics Inc. AstraZeneca...
BioCentury | Sep 8, 2017
Company News

Aptevo regains rights to MOR209/ES414 from MorphoSys

...with MorphoSys AG (Xetra:MOR; Pink:MPSYY) granting the German company worldwide rights to APVO414 (formerly MOR209/ES414). Aptevo...
...through Stage 1 of an ongoing Phase I trial to treat metastatic castration-resistant prostate cancer. Aptevo...
...8, 2016 ). Aptevo Therapeutics Inc. (NASDAQ:APVO), Seattle, Wash. MorphoSys AG (Xetra:MOR; Pink:MPSYY), Martinsried, Germany Business: Cancer Shannon Lehnbeuter MOR209/ES414 Aptevo Therapeutics Inc. Emergent...
BioCentury | Oct 24, 2016
Emerging Company Profile

RORing against resistance

...said. Breitmeyer declined to compare cirmtuzumab to other ROR1 inhibitors, including a bispecific protein from Aptevo Therapeutics Inc....
...of use for cirmtuzumab and TK216 Companies and Institutions Mentioned AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Aptevo Therapeutics Inc....
BioCentury | Aug 8, 2016
Company News

Emergent BioSolutions, Aptevo deal

...completed its spin out of newco Aptevo, which will house Emergent’s oncology and hematology assets. Aptevo’s...
...and CD3, which is in Phase I testing to treat metastatic castration-resistant prostate cancer. Aptevo...
...to develop ES414. Ixinity is a Factor IX replacement. Emergent shareholders received one share of Aptevo...
BioCentury | Aug 8, 2016
Financial News

Aptevo completes debt financing

...Hematology, Autoimmune Date completed: 2016-08-04 Type: Debt financing Raised: $20 million Investor: MidCap Financial Note: Aptevo...
BioCentury | Jan 22, 2016
Company News

Management tracks

...management team for planned oncology and hematology spinout Aptevo Therapeutics Inc. Emergent director Martin White will be Aptevo's...
Items per page:
1 - 9 of 9